In fact, some studies show that the VEGF signalling pathway was at least partly implicated, whereas others show that transdifferentiation was VEGF-independent, which could explain GBM resistance to anti-angiogenic therapies [11,12,34,35]. This evidence concerns the gene VEGFA and glioblastoma.